749
Views
30
CrossRef citations to date
0
Altmetric
Articles

Configuring the users of new HIV-prevention technologies: the case of HIV pre-exposure prophylaxis

Pages 428-439 | Received 06 Mar 2014, Accepted 27 Aug 2014, Published online: 01 Oct 2014

References

  • AkrichM.1992. “The De-Scription of Technical Objects.” In Shaping Technology–Building Society: Studies in Sociotechnical Change, edited by W. E.Bijker and J.Law, 205–224. Cambridge, MA: MIT Press.
  • ArnoldE. A., P.Hazelton, T.Lane, K. A.Christopoulos, G. R.Galindo, W. T.Steward, and S. F.Morin. 2012. “A Qualitative Study of Provider Thoughts on Implementing Pre-Exposure Prophylaxis (PrEP) in Clinical Settings to Prevent HIV Infection.” PLoS ONE7 (7)
  • BaetenJ., and R.Grant. 2013. “Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don't We Know?” Current HIV/AIDS Reports10 (2): 142–151.
  • BrooksR. A., R. J.Landovitz, R. L.Kaplan, E.Lieber, S.-J.Lee, and T. W.Barkley. 2012. “Sexual Risk Behaviors and Acceptability of HIV Pre-Exposure Prophylaxis among HIV-negative Gay and Bisexual Men in Serodiscordant Relationships: A Mixed Methods Study.” AIDS Patient Care and STDs26 (2): 87–94.
  • Centers for Disease Control and Prevention. 2011. “Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men.” Morbidity and Mortality Weekly Report60 (3): 65–68.
  • DavisM.2002. “HIV Prevention Rationalities and Serostatus in the Risk Narratives of Gay Men.” Sexualities5 (3): 281–299.
  • GilmoreH. J., A.Liu, K. A.Koester, K. R.Amico, V.McMahan, P.Goicochea, L.Vargas, D.Lubensky, S.Buchbinder, and R.Grant. 2013. “Participant Experiences and Facilitators and Barriers to Pill Use among Men Who Have Sex with Men in the iPrEx Pre-Exposure Prophylaxis Trial in San Francisco.” AIDS Patient Care and STDs27 (10): 560–566.
  • GrantR. M., J. R.Lama, P. L.Anderson, V.McMahan, A. Y.Liu, L.Vargas, P.Goicochea, et al. 2010. “Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.” New England Journal of Medicine363 (27): 2587–2599.
  • HoltM.2014. “HIV Pre-Exposure Prophylaxis and Treatment as Prevention: A Review of Awareness and Acceptability among Men Who Have Sex with Men in the Asia-Pacific Region and the Americas.” Sexual Health11 (2): 166–170.
  • JensenT. E.2012. “Intervention by Invitation: New Concerns and New Versions of the User in STS.” Science Studies25 (1): 13–36.
  • KarrisM. Y., S. E.Beekmann, S. R.Mehta, C. M.Anderson, and P. M.Polgreen. 2014. “Are We Prepped for Preexposure Prophylaxis (PrEP)? Provider Opinions on the Real-World Use of PrEP in the United States and Canada.” Clinical Infectious Diseases58 (5): 704–712.
  • KirbyT., and M.Thornber-Dunwell. 2014. “Uptake of PrEP for HIV Slow among MSM.” The Lancet383 (9915): 399–400.
  • KrakowerD., N.Ware, J. A.Mitty, K.Maloney, and K. H.Mayer. 2014. “HIV Providers' Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study.” AIDS & Behavior18 (9): 1712–1721.
  • LandowitzR. J.2012. “How PrEP Will Roll Out in Practice (Slowly, So Far).” Research Initiative Treatment Action!17 (2): 34–40.
  • LatourB.2005. Reassembling the Social: An Introduction to Actor Network Theory. Oxford: Clarendon.
  • LiuA., S.Cohen, S.Follansbee, D.Cohan, S.Weber, D.Sachdev, and S.Buchbinder. 2014. “Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco.” PLoS Medicine11 (3): e1001613.
  • McNeilD. G.2014. “Advocating Pill, U.S. Signals Shift to Prevent AIDS.” New York Times. http://nyti.ms/1jh5UbJ.
  • MimiagaM. J., E. F.Closson, V.Kothary, and J. A.Mitty. 2014. “Sexual Partnerships and Considerations for HIV Antiretroviral Pre-Exposure Prophylaxis Utilization among High-Risk Substance Using Men Who Have Sex with Men.” Archives of Sexual Behavior43 (1): 99–106.
  • MontgomeryC. M.2012. “Making Prevention Public: The Co-Production of Gender and Technology in HIV Prevention Research.” Social Studies of Science42 (6): 922–944.
  • MorinS. F., G.Yamey, and G. W.Rutherford. 2012. “HIV Pre-Exposure Prophylaxis.” BMJ345 (August 13): e5412.
  • OudshoornN., and T.Pinch. 2003. “User-Technology Relationships: Some Recent Developments.” In How Users Matter: The Co-Construction of Users and Technologies, edited by N.Oudshoorn and T.Pinch, 541–565. Cambridge, MA: MIT Press.
  • PaxtonL. A., T.Hope, and H. W.Jaffe. 2007. “Pre-Exposure Prophylaxis for HIV Infection: What If It Works?” The Lancet370 (9581): 89–93.
  • PerssonA.2013. “Notes on the Concepts of ‘Serodiscordance’ and ‘Risk’ in Couples with Mixed HIV Status.” Global Public Health8 (2): 209–220.
  • PottsA.2005. “Cyborg Masculinity in the Viagra Era.” Sexualities, Evolution & Gender7 (1): 3–16.
  • PoundP., N.Britten, M.Morgan, L.Yardley, C.Pope, G.Daker-White, and R.Campbell. 2005. “Resisting Medicines: A Synthesis of Qualitative Studies of Medicine Taking.” Social Science & Medicine61 (1): 133–155.
  • RaceK.2003. “Revaluation of Risk among Gay Men.” AIDS Education and Prevention15 (4): 369–381.
  • RosengartenM., and M.Michael. 2010. “HIV Pre-Exposure Prophylaxis (PrEP) and the Complexities of Biomedical Prevention: Ontological Openness and the Prevention Assemblage.” In HIV Treatment and Prevention Technologies in International Perspective, edited by M.Davis and C.Squire, 167–183. Basingstoke: Palgrave Macmillan.
  • SaberiP., K. E.Gamarel, T. B.Neilands, M.Comfort, N.Sheon, L. A.Darbes, and M. O.Johnson. 2012. “Ambiguity, Ambivalence, and Apprehensions of Taking HIV-1 Pre-Exposure Prophylaxis among Male Couples in San Francisco: A Mixed Methods Study.” PLoS ONE7 (11): e50061.
  • StadlerJ., and E.Saethre. 2011. “Blockage and Flow: Intimate Experiences of Condoms and Microbicides in a South African Clinical Trial.” Culture, Health & Sexuality13 (1): 31–44.
  • US Food and Drug Administration. 2012. FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection. Silver Spring, New Hampshire: US Department of Health & Human Services.
  • WoolgarS.1991. “Configuring the User: The Case of Usability Trials.” In A Sociology of Monsters: Essays on Power, Technology and Domination, edited by J.Law, 58–99. London: Routledge.
  • YouleM., and M. A.Wainberg. 2003. “Pre-Exposure Chemoprophylaxis (PrEP) as an HIV Prevention Strategy.” Journal of the International Association of Physicians in AIDS Care (JIAPAC)2 (3): 102–105.
  • YoungI., and L.McDaid. 2014. “How Acceptable are Antiretrovirals for the Prevention of Sexually Transmitted HIV?: A Review of Research on the Acceptability of Oral Pre-exposure Prophylaxis and Treatment as Prevention.” AIDS & Behavior18 (2): 195–216.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.